RxDoctor Payments Data

Danniell Hicks

Nurse Practitioner · Greenwood, DENPI 1649847583

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 42 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. 2025 is the largest year on record at $2,555, 3.1 times the $819 reported in 2022. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,295in general payments, 2019–2025

Across 304 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Insulet Corporation$791
  • Lilly USA, LLC$576
  • Mallinckrodt Hospital Products Inc.$329
  • Xeris Pharmaceuticals, Inc.$320
  • AbbVie$238
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,283100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,295 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$78,582
Medicare patients
298
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide684$1,202,060
JardianceEmpagliflozin499$607,618
TrulicityDulaglutide203$292,501
RybelsusSemaglutide101$163,510
MounjaroTirzepatide85$159,811
FarxigaDapagliflozin Propanediol86$98,494
Tresiba Flextouch U-200Insulin Degludec117$95,910
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog130$84,946
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog82$71,021
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/753$61,611
JanuviaSitagliptin Phosphate40$51,930
Tresiba Flextouch U-100Insulin Degludec106$51,752
Humalog Kwikpen U-200Insulin Lispro34$46,865
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog113$40,004
Soliqua 100-33Insulin Glargine/Lixisenatide36$37,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,537$1,372,417803 claims
Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Tradjenta$166$668,453547 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$576$458,826303 claims
AstraZenecaFarxiga$170$98,49486 claims
MerckJanuvia, Janumet$42$73,18964 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$183$37,83236 claims
Johnson & JohnsonInvokana$23$13,39614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Greenwood

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →